CN110746342A - 一种羟基内酰胺的制备方法 - Google Patents

一种羟基内酰胺的制备方法 Download PDF

Info

Publication number
CN110746342A
CN110746342A CN201910901614.XA CN201910901614A CN110746342A CN 110746342 A CN110746342 A CN 110746342A CN 201910901614 A CN201910901614 A CN 201910901614A CN 110746342 A CN110746342 A CN 110746342A
Authority
CN
China
Prior art keywords
reaction
catalyst
aryl
nmr
butoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910901614.XA
Other languages
English (en)
Other versions
CN110746342B (zh
Inventor
马保德
邵攀霖
吴超
王江
张绪穆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern University of Science and Technology
Original Assignee
Southern University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern University of Science and Technology filed Critical Southern University of Science and Technology
Priority to CN201910901614.XA priority Critical patent/CN110746342B/zh
Publication of CN110746342A publication Critical patent/CN110746342A/zh
Application granted granted Critical
Publication of CN110746342B publication Critical patent/CN110746342B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/62Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/66Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60Reduction reactions, e.g. hydrogenation
    • B01J2231/64Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/827Iridium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/842Iron

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

一种羟基内酰胺的制备方法,
Figure RE-DDA0002281462120000011
其由式(II)所示的环状酰亚胺通过均相催化氢化反应制得,
Figure RE-DDA0002281462120000012
其中,R1,R2,R3,分别独立为H,C1‑C12的烷基,芳基或者含杂原子取代的烷基,芳基,R1,R2也可以是通过环连接起来的C1‑C12的烷基,芳基或者含杂原子取代的烷基,芳基。本发明的催化剂转化数(TON,turnover number)高达100,000,与现有技术相比具有原子经济性高、绿色无污染、易于工业化等特点。

Description

一种羟基内酰胺的制备方法
技术领域
本发明涉及一种羟基内酰胺化合物的制备方法。
背景技术
羟基内酰胺是一种重要的有机化合物。一方面它作为酰亚胺阳离子前体,可以发生多种有机反应,生成具有重要作用的精细有机化工品。另一方面,该结构广泛存在于天然产物以及生物活性分子中,是一种优势的医药、农药等先导化合物的结构。甚至于该类结构已经是目前市场上一线用药的母核结构,例如目前应用广泛的安眠类药物佐匹克隆。
为了得到这类化合物,目前已经发展了一些方法,归纳起来主要有三类:一是通过金属或者金属氢化物还原环状酰亚胺化合物,代表性的试剂有锌,硼氢化钠等(Journal ofOrganic Chemistry,82(4),2193-2198;2017;Synthetic Communications,36(4),435-444;2006)。该类方法需要用到当量的还原试剂,反应对水敏感,后处理产生大量的三废,没有大规模应用潜力。二是通过硅烷、硼烷等非金属还原试剂还原(SyntheticCommunications,28(13),2507-2516; 1998)。该类方法也需要当量以上的还原剂,对水敏感,反应过程中产生的酸性气体对设备有较大腐蚀,后处理过程中三废量大,也不适宜工业化生产。三是通过催化氢化的方法。该类方法原子经济性高,副产物少,后处理简单,几乎无三废,是一种理想的方法。但目前该类方法的缺点是活性低,选择性差。例如非均相的钯炭催化剂,用量超过10%(WO 2007088189, WO 2009019281,WO 2008061955)。对于均相催化剂,S.H.Bergens等人(Journal of the American Chemical Society,132(37),12832-12834;2010)利用Noyori类型钌催化剂,成功实现了羟基内酰胺的制备,最低催化剂用量为0.02%。虽然该过程较为绿色,但催化剂用量大,成本高,达不到工业应用的要求。
发明内容
一方面公开一种环状酰亚胺均相催化氢化直接制备羟基内酰胺化合物的方法,通过本方法的实施,可以高效制备羟基内酰胺化合物,完全避免使用危险性试剂硼氢化钠等。
本发明通过以下技术方案实现:
一种羟基内酰胺化式(I)的制备方法,由式(II)所示环状酰亚胺在溶剂中,在碱存在下通过均相催化氢化反应制得
Figure RE-GDA0002299482120000011
其中,R1,R2,R3,分别独立为H,C1-C12的烷基,芳基或者含杂原子取代的烷基,芳基,R1,R2也可以是通过环连接起来的C1-C12的烷基,芳基或者含杂原子取代的烷基,芳基。
在一些实施例中,所述催化剂为配体和铱金属前体的原位配合物,其中配体的结构为具有(III)或(IV)结构的二茂铁配体,其中Ar为苯基,4-甲基苯基,3,5-二甲基苯基,3,5- 二甲基-4-甲氧基苯基;铱金属前体为[Ir(COD)Cl]2;溶剂为异丙醇、四氢呋喃、甲苯的一种或者任意比例的混合物,碱为叔丁醇钾、叔丁醇钠、叔丁醇锂、氢氧化钾、氢氧化钠、碳酸钠、碳酸钾、碳酸铯的一种或者任意比例混合物。
Figure BDA0002212003940000021
在一些实施例中,所述催化剂与环状酰亚胺的比例为1:5,000-100,000,优选1:20, 000-50,000。
在一些实施例中,所述溶剂为异丙醇、四氢呋喃、甲苯中的一种或几种组合,更优选异丙醇。
在一些实施例中,所述碱为叔丁醇钾,碱与环状酰亚胺的比例为1:5-100,优选1:10-50。
在一些实施例中,所述均相催化氢化反应的温度为20-80摄氏度,更优选40-60摄氏度。
在一些实施例中,所述均相催化氢化反应的氢气压力为1-10MPa,优选4-6MPa。
在一些实施例中,所述均相催化氢化反应的时间为10-30小时,优选20-25小时。
本发明采用弱给电子性的三齿配体与铱配合做催化剂,一方面通过三齿配位增强了催化剂的稳定性,不易失活,另一方面精细的调控了催化剂的活性,能够选择性活化一分子氢气对环状酰亚胺进行还原,一步反应专一生成羟基内酰胺化合物。同时与现有技术相比,本方法具有原子经济性高、选择性单一、三废少、易于工业化等特点。本发明的催化剂转化数(TON, turnover number)高达100,000,大幅度领先于目前该领域的所有已知催化剂,易于工业化放大。
具体实施方式
以下通过具体的实施例对本发明上述的内容作进一步的详细说明,但本发明不局限于实施例。
实施例1
在氩气气氛下往4.0mL的瓶中加入催化剂前体[Ir(COD)Cl]2(6.71mg,1.0×10- 2mmol,1 eq),配体(III)(2.4×10-2mmol,2.4eq)和无水异丙醇(iPrOH,2.0mL)。将混合物在在充满氩气的手套箱中25℃下搅拌12.0h,得到橙红色溶液,该催化剂溶液可以直接用来做催化反应。
实施例2
在氩气气氛下往4.0mL的瓶中加入催化剂前体[Ir(COD)Cl]2(6.71mg,1.0×10- 2mmol,1 eq),配体IV(2.4×10-2mmol,2.4eq)和无水异丙醇(iPrOH,2.0mL)。将混合物在在充满氩的手套箱中25℃下搅拌12.0h,得到橙红色溶液,该催化剂溶液可以直接用来做催化反应。
实施例3
Figure BDA0002212003940000031
在带磁子的玻璃试管中加入237mg 2-苄基异吲哚啉-1,3-二酮(1mmol),11.2mg叔丁醇钾,氮气保护下加入2毫升异丙醇,加入10微升0.01M的催化剂(S/C=10,000),充入4MPa 氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品232mg,收率97%。
白色固体,1H NMR(400MHz,d6-DMSO)δ7.71-7.69(m,1H),7.66-7.53(m,3H),7.53-7.29 (m,4H),7.28-7.23(m,1H),5.67(d,J=8.0Hz,1H),4.92(d,J=16Hz,1H),4.37(d,J=12Hz, 1H).13C NMR(101MHz,CDCl3)δ166.15,144.89,137.74,132.09,131.42,129.42,128.49, 127.68,127.11,123.76,122.47,80.28,42.11.
实施例4
Figure BDA0002212003940000032
在带磁子的玻璃试管中加入257mg 2-苄基-4-氯异吲哚啉-1,3-二酮(1mmol),11.2mg叔丁醇钠,氮气保护下加入2毫升四氢呋喃,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,80℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品251mg,两种异构体比例为2.5:1,收率97%。
白色固体。1H NMR(400MHz,d6-DMSO)δ7.69-7.53(m,3H),7.36-7.26(m,5H),7.53-7.29 (m,4H),7.28-7.23(m,1H),6.92(d,J=8.0Hz,0.3H),6.82(d,J=8.0Hz,0.7H),5.72(d,J=8.0 Hz,0.3H),5.66(d,J=8.0Hz,0.7H),4.93-4.85(m,1H),4.38-4.34(m,1H).13CNMR(101MHz, d6-DMSO)δ165.01,163.85,147.71,141.33,137.51,137.37,133.62,132.66,131.71,130.78, 129.44,129.08,128.60,128.56,127.78,127.27,127.22,127.10,122.88,121.56,79.64,79.31, 40.15.HRMS(ESI)calcd.for C15H12ClNO2[M+H]+:274.0557,Found:274.0628.
实施例5
在带磁子的玻璃试管中加入257mg 2-苄基-5-氯异吲哚啉-1,3-二酮(1mmol),6mg氢氧化钾,氮气保护下加入2毫升甲苯,加入2微升0.01M的催化剂(S/C=50,000),充入6MPa氢气,20℃反应30小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品246mg,两种异构体比例为1:1,收率95%。
白色固体。1H NMR(400MHz,CDCl3)δ7.54-7.39(m,3H),7.31-7.27(m,5H),5.56(d,J= 8.0Hz,1H),4.94-4.89(m,1H),4.29-4.25(m,1H),4.00-3.91(m,1H).13C NMR(101MHz,CDCl3)δ166.51,166.22,145.65,142.20,139.00,136.51,136.45,136.29,133.05,132.64,130.37, 129.73,128.98,128.61,128.57,127.99,127.97,124.88,124.60,124.20,123.60,80.81,80.65, 42.96.HRMS(ESI)calcd.for C15H12ClNO2[M+H]+:274.0557,Found:274.0629.
实施例6
在带磁子的玻璃试管中加入224mg 2-苯基异吲哚啉-1,3-二酮(1mmol),6mg氢氧化钠,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入10MPa氢气,30℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品220mg,收率97%。
白色固体。1H NMR(400MHz,d6-DMSO)δ7.78-7.67(m,5H),7.63-7.60(m,1H),7.46-7.42 (m,2H),7.23-7.19(m,1H),6.54(s,1H).13C NMR(101MHz,CDCl3)δ165.43,144.40,137.46, 132.75,131.28,129.67,128.66,124.64,123.66,122.83,122.30,81.87.
实施例7
Figure BDA0002212003940000043
在带磁子的玻璃试管中加入237mg 2-(对甲基苯)异吲哚啉-1,3-二酮(1mmol),6mg 氢氧化锂,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品230mg,收率96%。
白色固体。1H NMR(400MHz,d6-DMSO)δ7.78-7.67(m,5H),7.63-7.60(m,1H),7.46-7.42 (m,2H),7.23-7.19(m,1H),6.54(s,1H).13C NMR(101MHz,CDCl3)δ168.44,145.66,136.97, 135.54,133.99,132.70,130.92,130.48,125.08,124.63,124.15,84.37,21.04.
实施例8
Figure BDA0002212003940000051
在带磁子的玻璃试管中加入253mg 2-(4-甲氧基苯)异吲哚啉-1,3-二酮(1mmol),10mg 叔丁醇锂,氮气保护下加入2毫升异丙醇,加入20微升0.01M的催化剂(S/C=5,000),充入1MPa氢气,60℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品250mg,收率98%。
白色固体;95%收率.1H NMR(600MHz,T-MeOD)δ7.81-7.79(m,1H),7.71-7.67(m,2H), 7.61-7.58(m,1H),7.54-7.52(m,2H),7.02-7.00(m,2H),6.31(s,1H),3.83(s,3H).13CNMR(150 MHz,T-MeOD)δ168.61,159.61,145.77,133.94,132.72,130.92,130.79,127.32,124.65,124.14, 115.26,84.82,55.93.
实施例9
Figure BDA0002212003940000052
在带磁子的玻璃试管中加入241mg 2-(2-氟苯)异吲哚啉-1,3-二酮(1mmol),11mg叔丁醇钾,氮气保护下加入2毫升甲苯,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品237mg,收率97%。
白色固体。1H NMR(400MHz,T-MeOD)δ7.82-7.80(m,1H),7.72-7.65(m,3H),7.62-7.58 (m,2H),7.46-7.40(m,1H),6.99-6.94(m,1H),6.45(s,1H).13C NMR(101MHz,CDCl3)δ168.36,165.46,163.04,145.45,140.34,140.24,135.44,134.36,132.37,131.25,131.16,131.06, 130.09,126.20,124.66,124.34,123.65,119.15,119.12,112.89,112.68,110.86,110.60,84.02, 71.42.
实施例10
Figure BDA0002212003940000053
在带磁子的玻璃试管中加入258mg 2-(5-氯吡啶)异吲哚啉-1,3-二酮(1mmol),11mg 碳酸钾,氮气保护下加入2毫升四氢呋喃,加入2微升0.01M的催化剂(S/C=50,000),充入6MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品251mg,收率96%。
白色固体。1H NMR(400MHz,CDCl3)δ8.59(d,J=8.0Hz,1H),8.34(d,J=4.0Hz,1H),7.91-7.89(m,1H),7.79-7.76(m,1H),7.72-7.67(m,2H),7.60-7.56(m,1H),6.73(d,J=4.0Hz, 1H),5.52(d,J=4.0Hz,1H).13C NMR(101MHz,CDCl3)δ166.48,150.39,146.06,142.20, 138.77,133.68,131.73,130.33,126.99,124.30,123.81,115.12,82.30.
实施例11
Figure BDA0002212003940000061
在带磁子的玻璃试管中加入251mg 2-(2-甲基苄基)异吲哚啉-1,3-二酮(1mmol),15mg 叔丁醇钠,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品249mg,收率98%。
白色固体。1H NMR(400MHz,T-MeOD)δ7.79-7.76(m,1H),7.66-7.54(m,3H),7.23-7.08 (m,4H),5.66(s,1H),5.06(d,J=16Hz,1H),4.38(d,J=12Hz,1H),2.31(d,J=4Hz,3H).13C NMR(101MHz,T-MeOD)δ169.26,146.13,139.59,138.39,133.66,132.61,130.78,129.73, 129.66,129.25,126.17,124.68,123.94,82.07,43.61,21.42.HRMS(ESI)calcd.for C16H15NO2 [M+H]+:254.1103,Found:254.1175.
实施例12
Figure BDA0002212003940000062
在带磁子的玻璃试管中加入251mg 2-(3-甲基苄基)异吲哚啉-1,3-二酮(1mmol),10mg 甲醇钠,氮气保护下加入2毫升甲苯,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品248mg,收率98%。
白色固体。1H NMR(400MHz,CDCl3)δ7.62-7.60(m,1H),7.56-7.54(m,2H),7.46-7.43(m, 1H),7.16-7.13(m,4H),5.50(s,1H),4.68(d,J=16Hz,1H),4.21(d,J=16Hz,1H),2.31(s,3H). 13C NMR(101MHz,CDCl3)δ167.47,144.25,136.63,134.46,132.48,131.16,130.64,129.75, 128.85,127.84,126.30,123.62,123.44,81.14,40.32,19.34.HRMS(ESI)calcd.for C16H15NO2 [M+H]+:254.1103,Found:254.1174.
实施例13
Figure BDA0002212003940000071
在带磁子的玻璃试管中加入251mg 2-(4-甲基苄基)异吲哚啉-1,3-二酮(1mmol),12mg 甲醇钾,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入 4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品249mg,收率98%。
白色固体。1H NMR(400MHz,CDCl3)δ7.64-7.63(m,1H),7.55-7.54(m,2H),7.46-7.43(m, 1H),7.20-7.18(m,2H),7.10-7.08(m,2H),5.57(s,1H),4.80(d,J=16Hz,1H),4.19(d,J=12Hz, 1H),2.30(s,3H).13C NMR(101MHz,CDCl3)δ167.43,144.09,137.49,133.87,132.43,131.47, 129.86,129.52,128.60,123.53,123.49,81.07,42.49,21.22.
实施例14
Figure BDA0002212003940000072
在带磁子的玻璃试管中加入161mg 2-甲基异吲哚啉-1,3-二酮(1mmol),6mg氢氧化钠,氮气保护下加入2毫升甲苯,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气, 40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品158mg,收率97%。
白色固体。1H NMR(400MHz,CDCl3)δ7.60-7.58(m,1H),7.56-7.52(m,2H),7.42-7.38(m, 1H),5.29(s,1H),2.91(s,3H).13C NMR(101MHz,CDCl3)δ167.70,143.92,132.27,131.55, 129.83,123.35,123.19,83.71,26.23.
实施例15
Figure BDA0002212003940000073
在带磁子的玻璃试管中加入189mg 2-正丙基异吲哚啉-1,3-二酮(1mmol),20mg碳酸铯,氮气保护下加入2毫升四氢呋喃,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品184mg,收率96%。
白色固体。1H NMR(400MHz,CDCl3)δ7.54-7.47(m,2H),7.43-7.41(m,1H),7.36-7.32(m, 1H),5.67(d,J=8.0Hz,1H),3.34-3.27(m,1H),3.17-3.10(m,1H),1.59-1.49(m,2H),0.83(t,J= 8.0Hz,3H).13C NMR(101MHz,CDCl3)δ170.26,144.11,132.08,131.44,129.53,123.31,13.04, 81.61,40.67,21.48,11.43.
实施例16
Figure BDA0002212003940000081
在带磁子的玻璃试管中加入203mg 2-异丁基异吲哚啉-1,3-二酮(1mmol),10mg叔丁醇锂,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品198mg,收率97%。
白色固体。1H NMR(400MHz,CDCl3)δ7.62-7.54(m,3H),7.46-7.42(m,1H),5.74(s,1H), 3.30-3.24(m,1H),3.15-3.10(m,1H),2.07-2.00(m,1H),0.95(d,J=4.0Hz,3H),0.84(d,J=4.0 Hz,3H).13C NMR(101MHz,CDCl3)δ168.17,134.45,131.49,123.07,44.77,27.44.
实施例17
Figure BDA0002212003940000082
在带磁子的玻璃试管中加入203mg 2-叔丁基异吲哚啉-1,3-二酮(1mmol),23mg甲醇钾,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品199mg,收率98%。
白色固体。1H NMR(400MHz,CDCl3)δ7.77-7.68(m,1H),7.53-7.44(m,3H),6.00(d,J= 4.0Hz,1H),1.61(s,3H).13C NMR(101MHz,CDCl3)δ168.06,143.62,132.82,132.14,129.66, 123.16,122.83,82.41,54.89,28.72.
实施例18
在带磁子的玻璃试管中加入257mg 2-(2-氟苄基)异吲哚啉-1,3-二酮(1mmol),9mg 碳酸锂,氮气保护下加入2毫升甲苯,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品253mg,收率98%。
白色固体。1H NMR(400MHz,d6-DMSO))δ7.63-7.55(m,1H),7.47-7.43(m,1H),7.53-7.29 (m,4H),7.26-7.21(m,2H),7.06-6.99(m,2H),5.64(s,1H),4.62(d,J=16Hz,1H),4.42(d,J=16 Hz,1H).13C NMR(101MHz,CDCl3)δ167.70,162.16,159.71,144.15,132.57,131.10,130.76, 130.73,129.84,129.61,129.53,124.49,124.45,123.86,123.71,123.64,123.47,115.68,115.46, 81.46,81.45,36.38,36.34.HRMS(ESI)calcd.forC15H12FNO2[M+H]+:258.0852,Found: 258.0924.
实施例19
Figure BDA0002212003940000091
在带磁子的玻璃试管中加入300mg 2-(4-溴苯)异吲哚啉-1,3-二酮(1mmol),10mg叔丁醇锂,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品295mg,收率98%。
白色固体。1H NMR(600MHz,T-MeOD)δ7.83-7.81(m,1H),7.72-7.70(m,4H),7.62-7.58 (m,3H),6.46(s,1H),4.60(s,3H).13C NMR(150MHz,T-MeOD)δ168.34,145.56,137.78,134.31,132.95,132.44,131.07,125.88,124.69,124.32,119.50,84.05.
实施例20
Figure BDA0002212003940000092
在带磁子的玻璃试管中加入241mg 2-(3-氟苯)异吲哚啉-1,3-二酮(1mmol),11mg叔丁醇钾,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品237mg,收率97%。
白色固体。1H NMR(400MHz,T-MeOD)δ7.84-7.82(m,1H),7.73-7.70(m,2H),7.69-7.67 (m,1H),7.63-7.60(m,2H),7.47-7.43(m,1H),7.00-6.97(m,1H),6.49(s,1H).13C NMR(101 MHz,CDCl3)δ168.39,165.10,163.49,145.54,140.38,140.31,134.38,132.43,131.26,131.20, 131.08,124.70,124.36,119.21,119.19,112.88,112.74,110.87,110.70,84.07.
实施例21
Figure BDA0002212003940000101
在带磁子的玻璃试管中加入357mg 2-(4-氯苯)异吲哚啉-1,3-二酮(1mmol),10mg叔丁醇锂,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品251mg,收率97%。
白色固体。1H NMR(600MHz,d6-DMSO)δ7.84-7.82(m,2H),7.78-7.77(m,1H),7.74-7.72 (m,1H),7.69-7.68(m,1H),7.62-7.60(m,1H),7.51-7.50(m,2H),6.92-6.91(m,1H),6.53(d,J= 4.0Hz,1H).13C NMR(150MHz,d6-DMSO)δ165.56,144.29,136.48,133.01,131.05,129.82, 128.65,128.57,123.72,123.54,122.98,81.95.
实施例22
Figure BDA0002212003940000102
在带磁子的玻璃试管中加入241mg 2-(4-氟苯)异吲哚啉-1,3-二酮(1mmol),11mg叔丁醇钾,氮气保护下加入2毫升异丙醇,加入2微升0.01M的催化剂(S/C=50,000),充入4MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品238mg,收率98%。
白色固体。1H NMR(600MHz,T-MeOD)δ7.82-7.81(m,1H),7.72-7.69(m,4H),7.62-7.59 (m,1H),7.21-7.18(m,2H),6.40(s,1H).13C NMR(150MHz,CDCl3)δ168.50,162.87,161.25, 145.70,134.46,134.44,134.16,132.51,131.00,127.16,127.10,124.69,124.26,116.64,116.49, 84.56.
实施例23
在带磁子的玻璃试管中加入175mg 1-苯基吡咯烷-2,5-二酮(1mmol),5.6mg氢氧化钾,氮气保护下加入2毫升四氢呋喃,加入5微升0.01M的催化剂(S/C=20,000),充入2MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品170mg,收率96%。
白色固体。1H NMR(600MHz,CDCl3)δ7.13-7.31(m,5H),5.82-5.89(m,1H),2.12-7.49(m, 4H).13C NMR(150MHz,CDCl3)δ174.91,137.32,128.95,128.08,127.54,81.87,27.78,25.90.
实施例24
Figure BDA0002212003940000111
在带磁子的玻璃试管中加入323mg 1-萘基-苯并异吲哚啉-1,3-二酮(1mmol),4.0mg氢氧化钠,氮气保护下加入2毫升四氢呋喃,加入2微升0.01M的催化剂(S/C=50,000),充入2MPa氢气,40℃反应24小时。反应结束后,自然冷却至室温,小心放掉氢气,硅藻土过滤,滤液脱去有机溶剂后得产品315mg,收率97%。
白色固体。1H NMR(400MHz,d6-DMSO)δ8.38-8.01(m,4H),7.73-7.55(m,4H),7.46-6.99 (m,2H),7.23-7.19(m,3H),6.84(s,1H).13C NMR(101MHz,CDCl3)δ167.01,142.74,136.21, 134.32,132.42,133.63,133.05,129.04,128.67,128.31,127.83,127.63,127.12,126.16,125.89, 125.34,124.75,121.02,119.07,104.09,91.8。

Claims (10)

1.一种羟基内酰胺化式(I)的制备方法,由式(II)所示环状酰亚胺在溶剂中,在碱存在下通过均相催化氢化反应制得
Figure RE-FDA0002299482110000011
其中,R1,R2,R3,分别独立为H,C1-C12的烷基,芳基或者含杂原子取代的烷基,芳基,R1,R2也可以是通过环连接起来的C1-C12的烷基,芳基或者含杂原子取代的烷基,芳基。
2.根据权利1所述的制备方法,所述均相催化氢化反应的催化剂为配体和铱金属前体原位络合得到,配体的结构为具有(III)或(IV)结构的二茂铁配体,其中Ar为苯基,4-甲基苯基,3,5-二甲基苯基,3,5-二甲基-4-甲氧基苯基;铱金属前体为[Ir(COD)Cl]2,配体与金属的比例为2.0-2.4∶1
Figure RE-FDA0002299482110000012
3.根据权利1所述的制备方法,所述的溶剂为异丙醇、四氢呋喃、甲苯的一种或者任意比例的混合物。
4.根据权利1所述的制备方法,所述的碱为叔丁醇钾、叔丁醇钠、叔丁醇锂、氢氧化钾、氢氧化钠、碳酸钠、碳酸钾、碳酸铯的一种或者任意比例混合物。
5.根据权利1或2所述的制备方法,所述催化剂与环状酰亚胺的比例为1∶20,000-50,000。
6.根据权利1或3所述的制备方法,所述的溶剂为异丙醇。
7.根据权利1或4所述的制备方法,所述的碱为叔丁醇钾,所述碱与环状酰亚胺的比例为1∶10-50。
8.根据权利1所述的制备方法,所述均相催化氢化反应的温度为20-80摄氏度,更优选40-60摄氏度。
9.根据权利1所述的制备方法,所述均相催化氢化反应的氢气压力为4-6MPa。
10.根据权利1所述的制备方法,所述均相催化氢化反应的时间为20-25小时。
CN201910901614.XA 2019-09-23 2019-09-23 一种羟基内酰胺的制备方法 Active CN110746342B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910901614.XA CN110746342B (zh) 2019-09-23 2019-09-23 一种羟基内酰胺的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910901614.XA CN110746342B (zh) 2019-09-23 2019-09-23 一种羟基内酰胺的制备方法

Publications (2)

Publication Number Publication Date
CN110746342A true CN110746342A (zh) 2020-02-04
CN110746342B CN110746342B (zh) 2023-05-16

Family

ID=69276904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910901614.XA Active CN110746342B (zh) 2019-09-23 2019-09-23 一种羟基内酰胺的制备方法

Country Status (1)

Country Link
CN (1) CN110746342B (zh)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUOXIAN GU ET AL.: "Enantioselective Iridium-Catalyzed Hydrogenation of α-Keto Amides to α-Hydroxy Amides", 《ORG. LETT.》 *
HUIFANG NIE ET AL.: "Asymmetric hydrogenation of aromatic ketones using an iridium(I) catalyst containing ferrocene-based P–N–N tridentate ligands", 《TETRAHEDRON: ASYMMETRY》 *
SATOSHI TAKEBAYASHI ET AL.: "Desymmetrization of meso-Cyclic Imides via Enantioselective Monohydrogenation", 《J. AM. CHEM. SOC.》 *

Also Published As

Publication number Publication date
CN110746342B (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
JP2002527443A (ja) 有機ホウ素誘導体、及び有機化合物をカップリングさせる方法
CN107935812B (zh) 钌催化烷基芳酮与二苯乙炔反应制备多芳取代萘衍生物的方法
CN103071533A (zh) 一种pnn配体-铁络合物催化剂及其制备方法和应用
Madasu et al. Potassium tert-butoxide mediated C–C, C–N, C–O and C–S bond forming reactions
CN108250153B (zh) 一种反式双取代烯烃的制备方法
CN110590820B (zh) 手性有机硼化合物的制备方法
Franzén et al. Stereoselective palladium-catalyzed carbocyclization of allenic allylic carboxylates
CN110746342B (zh) 一种羟基内酰胺的制备方法
KR102207333B1 (ko) 4중 연속 고리 화합물의 신규한 제조방법
Shuai et al. Nickel-Catalyzed Favorskii-Type Rearrangement of Cyclobutanone Oxime Esters to Cyclopropanecarbonitriles
CN110734384B (zh) 一种羟基酰胺的制备方法
CN112275322B (zh) 一种负载型CNTs@NHC-Cu催化材料的制备方法及其应用
CN109762007A (zh) 一种合成n-取代-1,2,5,6-四氢吡啶-4-硼酸酯的工艺方法
CN110590690B (zh) 一种通过铜催化的sp2杂化碳氢键的烯基化反应方法
CN112430228B (zh) 一种手性2,3-二氢苯并[b]噻吩1,1-二氧化物、衍生物及制备方法
CN114805416A (zh) 一种炔丙基α-胺基硼酸酯化合物的制备方法
CN111978245A (zh) 一种3-氟-2-异丁基吡啶的制备方法
CN113845509A (zh) 吲哚基取代螺[环丁烷-1,1′-茚]类化合物的合成方法
CN110526862B (zh) 一类分子笼化合物及其制备方法与应用
CN113387837B (zh) 光氧化还原催化方法
CN114773229B (zh) 一种1,6二烯类化合物及其制备方法与应用
CN111138465A (zh) 1-硼烷基甲基-6-芳基-3-苯磺酰基-3-氮杂双环己烷衍生物的合成方法
CN113024604B (zh) 一种c3-烯基化的2-吡啶酮类衍生物的制备方法
CN114632552B (zh) Buchwald预催化剂及其制备方法与应用
CN113200812B (zh) 1,3,5-三取代芳基化合物的合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant